Abstract: The efficacy of onabotulinumtoxinA (OnaB-A) as a preventative treatment for chronic migraine, emerging fortuitously from clinical observation is now supported by class one evidence and over two decades of real-world clinical data. There is still limited ability to predict a clinically meaningful response to OnaB-A for individual patients, however. This review summarises briefly the proposed mechanism of OnaB-A in chronic migraine, the literature of predictors of clinical response, and recent developments in the field.

Keywords: migraine; botulinum toxin; predictors of efficacy

1. Introduction

Migraine is the most common disabling neurological condition, which globally in 2016 affected over one billion people, causing 45.1 million years lived with disability [1]. Migraine may be classified as either episodic or chronic; patients with episodic migraine experience fewer than 15 headache days per month while patients with chronic migraine suffer 15 or more headache days per month, of which at least eight fulfil the International Classification of Headache disorders (ICHD-3) criteria for migraine [2]. Every year, 2.2–3.1% of patients with episodic migraine progress to chronic migraine, and it is estimated that 1–4% of the population meets the criteria for chronic migraine [3].

The treatment of chronic migraine includes the need for effective preventative treatment in order to reduce the number of attacks and thereby burden of the disease. OnabotulinumtoxinA (OnaB-A) has emerged as an effective preventative treatment of chronic migraine for many patients; however, predicting efficacy for individual patients remains challenging. In this paper, we review the use of OnaB-A in the treatment of chronic migraine, its efficacy, predictors of response, clinical considerations, and future directions.

2. A Brief History of Botulinum Toxin

Botulinum toxin is one of the deadliest substances on earth. Its discovery as a therapeutic for migraine therefore was accidental and fortuitous. Botulinum toxin has seven serotypes (A–G) and is produced by clostridium botulinum, a Gram-positive anaerobic bacterium. Biological activity occurs at approximately 1 ng (a billionth of a gram), and the human median lethal dose (LD50) for inhalation botulism is 1–3 ng/kg [4,5]. Accordingly, one tablespoon of botulinum toxin would supply the world for one year [4].

The first scientific description of botulism was made by Dr. Kerner during the Napoleonic war (1795–1813), who described following the ingestion of contaminated meat, vomiting, intestinal spasm, ptosis, strabismus, dysphagia leading to flaccid paralysis
and respiratory failure. Dr. Kerner even hypothesised that this toxin could be used therapeutically [6]. Botulinum toxin was not isolated until late in the 19th century by Emile Pierre-Marie van Ermengem [7].

The first use of botulinum toxin therapeutically, as foreshadowed by Dr. Kerner would be by Dr. Scott in the treatment of strabismus [8]. Since then, it has been employed in the treatment of a number of conditions including muscle spasticity and hyperhidrosis. However, it was in the 1990s that Dr. Binder, a facial-plastic surgeon noted that some patients who were administered botulinum toxin for cosmesis reported an improvement in their migraine [9]. A number of open-label and observational studies with a variety of injection techniques followed, ultimately culminating in the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) study, which would provide class one evidence for the use of onabotulinumtoxinA (OnaB-A) in chronic migraine, FDA approval in 2010, and the ‘PREEMPT’ injection paradigm still used today (Figure 1) [10,11].

![Figure 1](image_url). The PREEMPT protocol for injection of onabotulinumtoxinA (stylised)—green dots represent injection sites [12].

3. Mechanism of Action

Botulinum toxin induces flaccid paralysis due to its affinity for skeletal and autonomic cholinergic nerve terminals. Botulinum toxin is internalised inside the synaptic vesicles (SV) of the presynaptic membrane. Botulinum toxins affinity to SV contribute both to its lethality and therapeutic efficacy, as hyperactive nerve terminals have a higher rate of SV endocytosis, favouring internalisation. Once internalised, botulinum toxin cleaves nine amino acids from the C-terminus of the Soluble NSF-Attachment Protein Receptor (SNARE) protein SNAP25, disrupting exocytosis and thereby inhibiting the release of acetylcholine, causing a chemical denervation and muscle relaxation/paralysis (see Figure 2) [13,14].

The mechanisms by which OnaB-A prevents chronic migraine are multifaceted and incompletely understood. Within the cranial sensory neurons, OnaB-A impairs nociception transmission by inhibiting the release of calcitonin gene related peptide (CGRP), substance P and glutamate again by cleaving SNAP25, suppressing peripheral sensitisation, with a secondary inhibitory effect on development and maintenance of central sensitisation [11,13].

Furthermore, OnaB-A interferes with ion channels including transient receptor potential cation channel vanilloid subfamily, member 1 (TRPV1), and transient receptor potential cation channel ankyrin subfamily, member 1 (TRPA1), impairing their delivery to the terminal membrane and thus downregulating receptor activity. This has a further positive impact on migraine by reducing trafficking primarily in c-type meningeal nociceptors [11].

It has also been demonstrated that OnaB-A has a direct central effect, despite the fact that it does not cross the blood–brain barrier. Through retrograde axonal transport, OnaB-A has been shown to travel to not only sensory ganglia but also to afferent innervations of the brain stem and cleave SNARE within central nervous system neurons [14].
4. Efficacy of OnabotulinumtoxinA

Class one evidence for botulinum toxin was established in the PREEMPT-1 and PREEMPT-2 studies. Patients aged 18–65 with chronic migraine, excluding patients with continuous headache were randomised to receive 155–195 units of OnaB-A in 31 sites over the head and neck. Between the studies, 1384 subjects were randomised to either OnaB-A or placebo. In pooled analysis, 24 weeks of OnaB-A was found to significantly reduce monthly headache days (MHD) by 8.4 compared to 6.6 with placebo, and a 50% responder rate (the proportion of the study population to achieve at least a 50% reduction in monthly migraine days) of 47.1% (placebo 35.1%) [10].

The efficacy of OnaB-A in chronic migraine has been confirmed in numerous real-world studies and subjected to several meta-analyses. In a 2018 Cochrane review of 28 randomised control trials (RCTs), OnaB-A for chronic migraine reduced the number of migraine days by 3.1 (95% CI 1.4–4.7) and headache days by 1.9 (95% CI 1.0–2.7) after six months [15]. The long-term efficacy of OnaB-A in chronic migraine was assessed in the REPOSE study, a 24-month open-label study of 641 subjects. MHD was reduced from a mean baseline of 20.5 to 7.4 after 24 months, with corresponding improvement in quality-of-life measures [16]. Three meta-analyses have not found efficacy for OnaB-A in episodic migraine [15,17,18].

The most common adverse events in the REPOSE study from OnaB-A include eyelid ptosis (5.4%), neck pain (2.8%) and musculoskeletal stiffness (2.7%). On meta-analysis, the risk ratio of any adverse event across 15 RCTs was 1.28 (95% CI 1.12–1.47) and included ptosis (RR 7.29, 95% CI 3.18–16.73), muscle weakness (RR 13.67, 95% CI 6.73–27.75), neck pain, (RR 2.98, 95% CI 2.06–4.32) and injection site pain (RR 2.10, 05% CI 1.02–4.32).

4.1. Quality of Life Measures

While emphasis is placed on reducing the frequency of headache days, improvement of quality of life, the burden of disease and reduction in mental health comorbidity are critical outcomes for both patients and treating clinicians. The 2-year COMPEL study included the patient health questionnaire (PHQ-9) and generalised anxiety disorder (GAD-7) score and found, respectively, that 78% and 81.5% of patients had significant reduction in symptoms of depression and anxiety, while other studies have reported improvement from even the first cycle of treatment [19,20].

Quality of life measures of OnaB-A therapy have been assessed in multiple studies utilising several measures including the headache impact test (HIT-6), migraine disability
assessment test (MIDAS) and migraine-specific quality of life questionnaire (MSQ). A clinically meaningful reduction in HIT-6 (reduction ≥5) has been reported in 30.1–59.1% of patients in trials [21,22], while MIDAS scores reduce significantly from 67.3 to 15.3 by 6 months in real-world setting [23]. Role function domains of the MSQ improve by 14.4–33 with OnaB-A [22,24].

4.2. Efficacy Compared to Other Treatments

Three RCTs have compared the efficacy of OnaB-A to other established preventative treatments for chronic migraine. Two RCTs of 59 and 60 participants respectively compared OnaB-A to topiramate at a daily dose of 100–200 mg. Both groups reported similar efficacy; however, OnaB-A was associated with fewer adverse events [25,26]. A third RCT of 59 patients compared OnaB-A to sodium valproate 250mg BID and reported similar efficacy between groups, with fewer adverse events in the OnaB-A group [27].

As outlined in Table 1, earlier initiation of onaB-A in the course of the disease is associated with a favourable outcome; however, practically, several jurisdictions have differing requirements before commencing onaB-A. The comparative efficacy of OnaB-A and the new CGRP monoclonal antibodies (mAb) has not been assessed in clinical trials. A retrospective US claims analysis suggested that patients treated with erenumab had fewer healthcare visits related to migraine compared to OnaB-A; however, further studies are required [28]. There is insufficient evidence to make a categorical recommendation of one therapy over the other in patients who have failed to respond to oral preventative treatment. Some experts have suggested an approach of commencing onaB-A and transitioning to CGRP mAb where response is sub-optimal [29]. There is also pre-clinical data to suggest that dual therapy may be beneficial, with OnaB-A mainly inhibiting c-fibres in the trigeminovascular system, and CGRP mAb Aβ-fibres [30]. A protocol for a network meta-analysis comparing OnaB-A and CGRP mAb is planned and may provide some clarification on relative efficacy [31].

Table 1. Predictors of efficacy of onabotulinumtoxinA in chronic migraine.

| Study                        | Population       | Diagnosis | MOH | Therapy       | Follow-Up (Months) | Definition of Response | Percentage Responders | Significant Predictors                                      | Non-Significant Predictors |
|------------------------------|------------------|-----------|-----|---------------|--------------------|------------------------|------------------------|------------------------------------------------------------|-----------------------------|
| Eren, 2020                   | Germany, n = 49  | 100% CM   | U   | 155 units OnaB-A PREEMPT | 3                 | ≥30% fewer MHD        | 38.8%                  | None                                                      | Triptan efficacy           |
| Dominéz-Vivero, 2020         | Spain, n = 62    | 100% CM   | U   | 155 units OnaB-A PREEMPT | 3                 | ≥50% fewer headaches  | 75.8%                  | Age, CRP (>50 ng/mL), PTX3 (>1000 pg/mL), iron deposition in GP and PAG | Gender, BMI, smoking, phenotype (intensity, aura, duration), allodynia, presence or location of WML |
| Moreno-Mayordomo, 2019       | Spain, n = 156   | 100% CM   | U   | 155 units OnaB-A PREEMPT | 6                 | ≥50% fewer MMD        | 76.9%                  | Polymorphisms CALCA rs781719 TRPV1 rs222749, 23 other SNPs |                                                   |
| Schiano di Cola, 2019        | Italy, n = 84    | 100% CM   | 65.5% | 155–195 units OnaB-A PREEMPT | 12                | ≥50% fewer headaches  | 73.9%                  | Depressive symptoms, MOH                                   | N/A                         |
| de Tommaso, 2019             | Italy, n = 120   | 100% CM   | U   | 155–195 units OnaB-A PREEMPT | 24                | ≥50% fewer headaches  | 61.6%                  | Less severe allodynia                                      | N/A                         |
| Young, 2019                  | USA, Aus, Korea, n = 715 | 100% CM   | U   | 155 units OnaB-A PREEMPT | 27                | Mean reduction MHD    | N/A                    | absence allodynia (only at 27 months)                     | N/A                         |
Table 1. Cont.

| Study             | Population                      | Diagnosis | MOH | Therapy          | Follow-Up (Months) | Definition of Response | Percentage Responders | Significant Predictors                                                                 | Non-Significant Predictors |
|-------------------|---------------------------------|-----------|-----|------------------|--------------------|------------------------|-----------------------|-----------------------------------------------------------------------------------------|-----------------------------|
| Dominguez, 2018   | Spain, n = 62                   | 100% CM   | U   | 155 units OnaB-A | PREEMPT            | ≥50% fewer headaches  | 75.8%                 | CGRP, PTH3                                                               | TNF-α, IL-10, IL-6, hs-CRP, cFns, S100, NSE |
| Dominguez, 2018   | Spain, n = 725                  | 100% CM   | U   | 155 units OnaB-A | PREEMPT            | ≥50% fewer headaches  | 79.3%                 | CM duration, Unilateral pain, combined symptomatic treatment, fewer days of disability, milder headache | Gender, MA, depression, fibromyalgia, |
| Lovati, 2018      | Italy, n = 44                   | 100% CM   | U   | 170–195 units    | OnaB-A             | ≥50% fewer MMD        | 31.8%                 | Triptan response                                                              | N/A                         |
| Hubbard, 2016     | USA, n = 23                     | 100% CM   | U   | 150 units modif. | OnaB-A             | ≥50% fewer MHD and now EM | 47.8%                 | Disease duration MCA/ICA ratio                                                      | N/A                         |
| Lee, 2016         | Korea, n = 70                   | 100% CM   | 50% R, 43% NR | 155 units OnaB-A | PREEMPT            | ≥50% fewer MHD, ≥50% fewer abortive Rx OR ≥50% fewer mod-severe headache | 60%                     | Age, gender, BMI, concurrent prophylactic medication, MA vs. MoA, psychiatric comorbidity, smoking | Clinical features (MA), age, duration of CM, comorbidity, obesity, prophylactic medication |
| Cernuda-Morollón, | Spain, n = 83                   | 100% CM   | 31.3% | 155–195 units    | OnaB-A             | ≥50% fewer headaches AND ≥50% reduced VAS | 77.1%                 | CGRP (76.85 pg/mL vs. 50.45 pg/mL), VIP | Phenotype (imploding pain) |
| Kim, 2010         | USA, n = 18                     | 88.9% EM  | 11.1% CM | 16-78 units     | OnaB-A             | ≥50% fewer headaches  | 72.2%                 | Phenotype of pain (imploding pain)                                                | N/A                         |
| Burstein, 2009    | USA, n = 82                     | 32.9% EM  | 67.1% CM | U                | U                  | ≥66.7% fewer MMD      | 45.1%                 | Phenotype of pain (imploding or ocular)                                            | EM vs. CM |
4.3. Efficacy in Hemiplegic Migraine

Hemiplegic migraine, a rare subtype of migraine with aura, has no RCT proven preventative treatment due to the rarity of the condition. The use of OnaB-A in hemiplegic migraine has been reported in two case studies and a case series of eleven patients. In the case series, 9 of the 11 patients reported a decrease in the frequency of their migraine aura [53].

4.4. Efficacy in Medication Overuse Headache

As seen in Table 1, Medication Overuse Headache (MOH) is a common comorbidity in patients with chronic migraine, and as such, the efficacy of OnaB-A in this population is of clinical interest [54,55]. In a RCT comparing OnaB-A to acute withdrawal of medication, OnaB-A was not superior to placebo at 12 weeks in either reduction in MMD (6.2 vs. 7.0) or MHD (26.9% vs. 20.5%) [56]. Conversely, treatment with OnaB-A appears to remain efficacious in populations with high rates of MOH [57]. In a UK study, 56.2% of patients with CM and MOH had a ≥30% reduction in MHD compared to 64.9% of patients with CM alone, further supporting its efficacy [58]. Accordingly, the European Headache Federation recommends that it is preferable to withdraw acute medication prior to the initiation of OnaB-A; however, where this is not feasible, OnaB-A may be commenced prior to or while withdrawing acute medication [59].

5. Factors Associated with Efficacy of Botulinum Toxin

5.1. Clinical Factors

A clinical biomarker of efficacy of OnaB-A in chronic migraine has remained of interest to clinicians for the past three decades, in order to allow best use of healthcare resources and plan treatment. A summary of published articles that have reported on efficacy of OnaB-A in chronic migraine is presented in Table 1. While several clinical, chemical, genetic and radiological predictors have been described in the literature, at present, there is insufficient data to guide treatment decisions or predict efficacy for an individual patient.

One of the first clinical predictors of efficacy was proposed by Jakubowski, who described three phenotypes of pain in migraine: ocular (‘like pushing a finger into my eye’), imploding (‘someone is crushing my skull’) and exploding (‘like my head is going...
to explode’). Jakubowski et al. reported a cohort of 63 patients with both episodic and chronic migraine, who received 100 units of OnaB-A, prior to the PREEMPT protocol. They reported that an ocular or imploding phenotype of pain was associated with response to OnaB-A, while exploding pain was not [51]. This observation was duplicated by Burstein et al. in 2009, Kim et al. in 2010 and Grogan et al. in 2013, all with mixed cohorts and a non-PREEMPT protocol [47–49]. Lin et al. failed to demonstrate a difference between imploding and exploding pain but again reported ocular pain to be predictive of response, while Pagola et al. found no such correlation [44,45].

The second phenotypic characteristics of interest has been unilateral pain, which was first reported by Mathew et al. to be predictive of response, along with cutaneous allodynia and pericranial muscle tenderness [50]. De Tommaso et al. also reported that less severe allodynia was a predictor of clinical response, as did Young et al., however, only on long-term follow-up [36,37]. Other studies, however, have failed to find that unilateral pain [45], allodynia [33] or neck muscle tenderness [51,52] predict response to OnaB-A.

Whether the phenotypic characteristics outlined above are predictors of clinical response, and their predictive value if so, remains unclear. Certainly, no patient should have OnaB-A withheld for lacking these characteristics. Presuming a predictive value of these features, one possible mechanism suggested is that unilateral ocular pain, in the presence of autonomic symptoms, is a marker of ongoing peripheral trigeminal activation and central sensitisation [60,61].

With interest in trigeminal activation as a marker of efficacy, response to triptans, which exert some effect in reducing CGRP release from trigeminal afferents, is also of clinical interest. Lovati et al. first published an observational study in 2018 which did demonstrate that triptan responsiveness was a predictor of efficacy in OnaB-A [40]. In an attempt to confirm these findings, a prospective study rating triptan efficacy prior to commencement of OnaB-A in 49 patients was performed, which found that triptan efficacy did not predict response to OnaB-A after three months treatment [32].

Finally, assessment of patient comorbidities appears poorly predictive of response to OnaB-A. Elevated body mass index (BMI), while a risk factor for chronification of migraine, does not appear to predict response [33,42–44]. A shorter duration of disease has been reported to be a predictive value in some studies [42,52], but not others [33,43]. Finally, the presence of depressive symptoms again has conflicting results [35,39,42,45].

### 5.2. Biomarkers

Supporting the prospect that trigeminal activation is associated with responsiveness to OnaB-A, two studies have found that patients with elevated levels of calcitonin gene-related peptide (CGRP) were predictive of response to OnaB-A, albeit with very different clinical ranges [33,38,43]. Pentraxin-related peptide (PTX3), a marker of endothelial dysfunction, has also been reported as a predictor of OnaB-A efficacy [38]. While interesting, testing of CGRP is not yet practical at the bedside.

### 5.3. Imaging Features

Several studies have attempted to address whether structural changes exist between responders and non-responders of OnaB-A therapy. Hubbard assessed structural and functional MRI changes in non-responders to OnaB-A compared to responders who had reverted to episodic migraine. They demonstrated that OnaB-A responders had cortical thickening in the right primary somatosensory cortex, anterior insula, left superior temporal gyrus and pars opercularis compared to non-responders [41]. Previous studies have reported reduced insular thickness in high-frequency episodic migraine and in chronic migraine compared to episodic [62,63]. As the study only evaluated patients post intervention, it is unclear whether these changes represent a differentiating feature of response or reactive structural change as responders revert to episodic migraine. As noted by the authors, further prospective study in this area would be useful.
In a second study of 62 patients with chronic migraine, iron deposition in the periaqueductal gray (PAG) was found to be associated with a negative response to OnaB-A [33]. Iron deposition has been shown to be increased in CM compared to EM and in EM compared to healthy controls, suggesting both that accumulation occurs with prolonged disease and a possible mechanism by which duration of disease is a marker of OnaB-A efficacy [64]. The mechanism by which iron deposition could affect the efficacy of OnaB-A is not known. One theory is that dysfunction of the PAG, which is involved in descending anti-nociceptive function, could taper response to the more peripheral effect of OnaB-A, or that iron deposition is a biomarker of a higher activation rate of pain-circuits and thus more refractory disease [33].

5.4. Genetic Markers

One study has assessed for 25 single nucleotide polymorphisms in 156 female patients with chronic migraine. Two polymorphisms were found to be associated with response to OnaB-A; CALCA rs3781719 (40.9% vs. 26.9%) and TRPV1 rs222749 (4.17% vs. 12.5%) [34]. Whilst not accounting for the entire population, these two genes which respectively encode CGRP and the TRPV1 receptor, a target of OnaB-A, support the mechanism of action of OnaB-A in chronic migraine.

6. Clinical Considerations

6.1. Assessment of Efficacy When Commencing Botulinum Toxin

There is general consensus amongst clinicians that a reduction in headache days by 30% to 50% is clinically meaningful and a marker of efficacy of OnaB-A, with the latter used as an outcome measure in the PREEMPT trials [65,66]. In pooled analysis of the PREEMPT studies, 49.3% of participants achieved a 50% reduction in MHD in their first cycle, while 11.3% and 10.3% of patients responded only after the second and third cycle, respectively [66].

Several studies have been undertaken to assess the cumulative efficacy of commencing OnaB-A beyond the first two cycles. In a single-centre prospective study of 56 patients, the proportion of patients with a 50% reduction in MHD doubled between cycle 2 and 5 (27 to 48%) [67]. In a retrospective cohort study of two Italian centres, response to OnaB-A at 6 months was only modestly predictive of response at 12 months (Cohen’s Kappa 0.51), and 23.8% of non-responders at 6 months were responders at 12 months [68]. The predictive value of responder status was further delineated by the Italian group in an open prospective study who found that 64.7% of patients who respond in the first three cycles have sustained response, while 23.4% of initial non-responders converted in cycle four or five [69]. On the basis of this, it is recommended to trial OnaB-A for 2–3 treatment cycles in order to assess efficacy; however, local jurisdictions have differing restrictions [59].

6.2. Wearing Off Effect of Botulinum Toxin

Response to OnaB-A is not uniform between 12-week injections but rather has a ‘U’ shape response with clear induction, peak-effect, and ‘wear-off’ phases [70]. Wear-off of OnaB-A is a common clinical phenomenon, presenting a challenge in management. Rates of wear-off of OnaB-A have been reported between 44–62.9% of patients, most commonly 2–4 weeks before the following injection. The driving mechanism of wear-off is not clear, with no differences in patient characteristics found to be predictive of wear-off [71,72]. The duration of biological effect of OnaB-A has been speculated, with pre-clinical evidence of reversal of neuromuscular blockade seen prior to 12 weeks and histological studies in essential blepharospasm showing resolution of fibre diameter by 12 weeks [73]. Nonetheless, the duration of clinical effect of OnaB-A seems to vary between relative short durations (dystonia) and much longer (neurogenic detrusor overactivity) [74,75].

Short-term bridging prophylactic strategies are most commonly employed to treat wear-off, including intramuscular ketorolac injections and peripheral nerve blocks [71]. Increasing the dose of OnaB-A may achieve a longer duration of response in up to 75% of
patients in one study [72]. Considering the frequency of OnaB-A injection for indications other than chronic migraine, it is possible that a more frequent treatment regimen may be efficacious. In treatment of cervical dystonia, blepharospasm and cosmesis, frequency of treatment varies between 8–10 weeks [71].

6.3. Stopping Botulinum Toxin

The European Headache Federation recommends considering stopping OnaB-A in patients who have less than ten MHD for three months [59]. In one prospective study, 49% of a cohort of 276 patients were withdrawn from OnaB-A after meeting the predefined criteria fewer than five MHD for two consecutive 12-week cycles and a MIDAS score of <10. Over six-months of follow-up, 80% of patients had no clinical worsening or need to resume preventative treatment [76]. In a smaller case series, OnaB-A was withdrawn in 54 patients who reverted to an episodic pattern, of whom 80% remained episodic migraine after six months [76].

7. Emerging Concepts

7.1. Location of Injections

The choice of sites in the PREEMPT protocol of seven specific muscle groups aligns with the peripheral nerve distribution of the trigeminal, occipital and cervical sensory nerves and has proven efficacy in chronic migraine [77]. As understanding of the mechanism of botulinum toxin in chronic migraine has evolved, alternate injection strategies have been speculated.

Injection of the sphenopalatine ganglion (SPG) has been proposed in order to target parasympathetic fibres and inhibition of acetylcholine release. A pilot study of injection of 50 units of OnaB-A into the SPG was found to be safe, and further study is ongoing (NCT04069897) [78].

In a recent anatomical study, the location of the four temporal injections has been suggested to be altered in order to improve efficacy by better corresponding with the surface anatomy of the auriculotemporal nerve and awaits clinical confirmation [79]. Finally, an alternate strategy of injecting OnaB-A to the cranial sutures with ultrasound guidance has been suggested. The author supports this approach based on pre-clinical studies in which meningeal nociceptor sensitivity is reduced with this approach and the concentration of extracranial pain fibres in proximity to suture sites [80]. Clinical study is required to further evaluate this hypothesis.

7.2. Current Studies

There are several studies ongoing involving the use of botulinum toxin in both primary and secondary headache disorders. Selected trials that are currently registered on www.clinicaltrials.gov (accessed 3 May 2021) are presented in Table 2

Table 2. Selected studies currently active involving botulinum toxin.

| Brief Study Synopsis                                      | Year Posted | Current Status     | Trial Identifier |
|-----------------------------------------------------------|-------------|--------------------|------------------|
| PraB-A for treatment of chronic migraine                  | 2021        | Recruiting         | NCT04845178      |
| OnaB-A for the treatment of post-stroke and vascular headache | 2020        | Not yet recruiting | NCT04580238      |
| 155 units vs. 100 units of OnaB-A for treatment of chronic migraine | 2020        | Recruiting         | NCT04349176      |
| OnaB-A blockade of the SPG for refractory chronic migraine | 2019        | Recruiting         | NCT04069897      |

PraB-A—prabotulinumtoxinA, OnaB-A—onabotulinumtoxinA, SPG—sphenopalatine ganglia.
8. Conclusions

The efficacy of onabotulinumtoxinA is clearly established as a treatment of chronic migraine. However, there remain several unanswered questions. Further work is required to assess prospectively markers of response and their inter-relationship, including iron deposition in the PAG and clinical duration of disease, unilateral pain, autonomic symptoms, allodynia and trigeminal activation and CGRP levels. Currently, there is insufficient evidence to accurately predict response to OnaB-A for an individual patient.

Further health-economic work is required to determine the optimal duration of a clinical trial of OnaB-A, with several studies suggesting the possibility of clinically meaningful response commencing after the second cycle. Considering the mechanism of action of OnaB-A, further studies optimising the PREEMPT protocol in an attempt to maximise its efficacy are also welcomed.

Author Contributions: Conceptualization, M.M.; methodology, J.C.R.; writing—original draft preparation, J.C.R.; writing—review and editing, M.M. and E.J.H. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: J.C.R. has received compensation from the Pharmaceutical Society of Australia, sponsored by Viatris for educational material. E.J.H. has served on advisory boards for Sanofi-Genzyme, Novartis, Teva, Eli Lilly, Allergan, Lundbeck, and has received payment for educational presentations from Allergan, Teva, Eli Lilly and Novartis. M.M. has served on advisory boards for Allergan, Autonomic Technologies Inc, Eli Lilly Novartis, Pfizer, Salvia and TEVA; has received payment for educational presentations from Allergan, electroCore, Eli Lilly, Novartis and TEVA; has received grants from Abbott, Medtronic and electroCore; and has a patent on system and method for diagnosing and treating headaches (WO2018051103A1, issued).

References

1. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2018, 17, 954–976. [CrossRef]
2. The International Classification of Headache Disorders 3rd edition. Available online: https://ichd-3.org/ (accessed on 12 August 2019).
3. Buse, D.C.; Greisman, J.D.; Baigi, K.; Lipton, R.B. Migraine progression: A Systematic Review. *Headache* 2019, 59, 306–338. [CrossRef]
4. Horowitz, B.Z. Botulinum toxin. *Crit. Care Clin.* 2005, 21, 825–839, viii. [CrossRef]
5. Whitcup, S.M. The History of Botulinum Toxins in Medicine: A Thousand Year Journey. *Handb. Exp. Pharmacol.* 2021, 263, 3–10.
6. Erbguth, F.J.; Naumann, M. Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the “sausage poison”. *Neurology* 1999, 53, 1850–1853. [CrossRef]
7. Van Ermengem, E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as “Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus” in Zeitschrift für Hygiene und Infektionskrankheiten 26: 1-56, 1897. *Rev. Infect. Dis.* 1979, 1, 701–719.
8. Scott, A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. *Ophthalmology.* 1980, 87, 1044–1049. [CrossRef]
9. Binder, W.J.; Blitzer, A.; Brin, M.F. Treatment of hyperfunctional lines of the face with botulinum toxin A. *Dermatol. Surg.* 1998, 24, 1198–1205. [CrossRef]
10. Aurora, S.K.; Dodick, D.W.; Turkel, C.C.; DeGryse, R.E.; Silberstein, S.D.; Lipton, R.B.; Diener, H.C.; Brin, M.F. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. *Headache* 2010, 50, 921–936. [CrossRef]
11. Whitcup, S.M.; Turkel, C.C.; DeGryse, R.E.; Brin, M.F. Development of onabotulinumtoxinA for chronic migraine. *Ann. N. Y. Acad. Sci.* 2014, 1329, 67–80. [CrossRef]
12. Available online: https://app.biorender.com/biorender-templates (accessed on 31 May 2021).
13. Frampton, J.E.; Silberstein, S. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. *Drugs* 2018, 78, 589–600. [CrossRef]
14. Pirazzini, M.; Rossetto, O.; Eleopra, R.; Montecucco, C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. *Pharmacol. Rev.* 2017, 69, 200–235. [CrossRef]
15. Herd, C.P.; Tomlinson, C.L.; Rick, C.; Scotton, W.J.; Edwards, J.; Ives, N.; Clarke, C.E.; Sinclair, A. Botulinum toxins for the prevention of migraine in adults. *Cochrane Database Syst. Rev.* 2018, 6, Cd011616. [CrossRef] [PubMed]
39. Domínguez, C.; Pozo-Rosich, P.; Torres-Ferrús, M.; Hernández-Beltrán, N.; Jurado-Cobo, C.; González-Oria, C.; Santos, S.; Monzón, M.J.; Latorre, G.; Álvaro, L.C.; et al. OnabotulinumtoxinA in chronic migraine: Predictors of response. A prospective multicentre descriptive study. Eur. J. Neurol. 2018, 25, 411–416. [CrossRef]

40. Lovati, C.; Giani, L.; Mariotti, D.A.C.; Tabaei Damavandi, P.; Mariani, C.; Pantoni, L. May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-A prophylaxis? Neurol. Sci. 2018, 39, 153–154. [CrossRef] [PubMed]

41. Hubbard, C.S.; Becerra, L.; Smith, J.H.; De Lange, J.M.; Smith, R.M.; Black, D.F.; Welker, K.M.; Burstyn, R.; Cutrer, F.M.; Borsook, D. Brain Changes in Responders vs. Non-Responders in Chronic Migraine: Markers of Disease Reversal. Front. Hum. Neurosci. 2016, 10, 497. [CrossRef]

42. Lee, M.J.; Lee, C.; Choi, H.; Chung, C.S. Factors associated with favorable outcome in botulinum toxin A treatment for chronic migraine: A clinic-based prospective study. J. Neurol. Sci. 2016, 363, 51–54. [CrossRef]

43. Cernuda-Morollón, E.; Ramón, C.; Martínez-Cambor, P.; Serrano-Pértiller, E.; Larroza, D.; Pascual, J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain 2015, 156, 820–824. [CrossRef] [PubMed]

44. Lin, K.H.; Chen, S.P.; Fuh, J.L.; Wang, Y.F.; Wang, S.J. Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: A retrospective study. J. Chin. Med. Assoc. 2014, 77, 10–15. [CrossRef] [PubMed]

45. Pagola, I.; Esteve-Belloch, P.; Palma, J.A.; Luquin, M.R.; Riverol, M.; Martinez-Vila, E.; Irimia, P. [Predictive factors of the response to treatment with onabotulinumtoxinA in refractory migraine]. Rev. Neurol. 2014, 58, 241–246. [PubMed]

46. Bumb, A.; Seifert, B.; Wetzel, S.; Agosti, R. Patients profiling for Botox®(onabotulinum toxin A) treatment for migraine: A look at white matter lesions in the MRI as a potential marker. Springerplus 2013, 2, 377. [CrossRef]

47. Grogan, P.M.; Alvarez, M.V.; Jones, L. Headache direction and aura predict migraine responsiveness to rimabotulinumtoxin B. Headache 2013, 53, 126–136. [CrossRef]

48. Kim, C.C.; Bogart, M.M.; Wee, S.A.; Burstein, R.; Arndt, K.A.; Dover, J.S. Predicting migraine responsiveness to botulinum toxin type A injections. Arch. Dermatol. 2010, 146, 159–163. [CrossRef]

49. Burstyn, R.; Dodick, D.; Silberstein, S. Migraine prophylaxis with botulinum toxin type A is associated with perception of headache. Toxicon 2009, 54, 624–627. [CrossRef]

50. Mathew, N.T.; Kailasam, J.; Meadows, L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008, 48, 194–200. [CrossRef]

51. Jakubowski, M.; MccAllister, P.J.; Bajwa, Z.H.; Ward, T.N.; Smith, P.; Burstyn, R. Exploding vs. imploding headache in patients with hemiplegic migraine: A randomized, placebo-controlled, double-blind, cross-over trial of botulinum toxin type A. Cephalalgia 2007, 27, 157–165. [CrossRef] [PubMed]

52. Eross, E.J.; Gladstone, J.P.; Lewis, S.; Rogers, R.; Dodick, D.W. Duration of migraine is a predictor for response to Botulinum Toxin A. Pain 2006, 125, 286–295. [CrossRef]

53. Chen, T.Y.; Garza, I.; Dodick, D.W.; Robertson, C.E. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients with Hemiplegic Migraine: Case Series of 11 Patients. Headache 2018, 58, 973–985. [CrossRef]

54. De Goffau, M.J.; Klaver, A.R.E.; Willemse, M.G.; Bindels, P.J.E.; Verhagen, A.P. The Effectiveness of Treatments for Patients with Medication Overuse Headache: A Systematic Review and Meta-Analysis. J. Pain 2017, 18, 615–627. [CrossRef]

55. Chiang, C.C.; Schwedt, T.J.; Wang, S.J.; Dodick, D.W. Treatment of medication-overuse headache: A systematic review. Cephalalgia 2016, 36, 371–386. [CrossRef]

56. Piipers, J.A.; Kies, D.A.; Louter, M.A.; van Zwet, E.W.; Ferrari, M.D.; Terwindt, G.M. Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: A double-blind randomized controlled trial. Brain 2019, 142, 1203–1214. [CrossRef]

57. Butera, C.; Colombo, B.; Bianchi, F.; Cursi, M.; Messina, R.; Amadio, S.; Guerriero, R.; Comi, G.; Del Carro, U. Refractory chronic migraine: Is drug withdrawal necessary before starting a therapy with onabotulinumtoxinA. Neurology 2019, 92, e1076–e1085. [CrossRef] [PubMed]
65. Tassorelli, C.; Aguggia, M.; De Tommaso, M.; Geppetti, P.; Grazzi, L.; Pini, L.A.; Sarchielli, P.; Tedeschi, G.; Martelletti, P.; Cortelli, P. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: Results of a survey of sixty-three Italian headache centers. J. Headache Pain 2017, 18, 66. [CrossRef] [PubMed]

66. Silberstein, S.D.; Dodick, D.W.; Aurora, S.K.; Diener, H.C.; DeGryse, R.E.; Lipton, R.B.; Turkel, C.C. Per cent of patients with chronic migraine who responded per onabotulinumtoxin A treatment cycle: PREEMPT. J. Neurol. Neurosurg. Psychiatry 2015, 86, 996–1001. [CrossRef]

67. Sarchielli, P.; Romoli, M.; Corbelli, I.; Bernetti, L.; Verzina, A.; Brahimì, E.; Eusebi, P.; Caproni, S.; Calabresi, P. Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine. Front. Neurol. 2017, 8, 655. [CrossRef]

68. Vernieri, F.; Paolucci, M.; Altamura, C.; Pasqualetti, P.; Mastrangelo, V.; Pierangelì, G.; Cevoli, S.; D’Amico, D.; Grazzi, L. Onabotulinumtoxin-A in Chronic Migraine: Should Timing and Definition of Non-Responder Status Be Revised? Suggestion from a Real-Life Italian Multicenter Experience. Headache 2019, 59, 1300–1309. [CrossRef]

69. Ornello, R.; Guerzoni, S.; Baraldi, C.; Evangelista, L.; Frattale, I.; Marini, C.; Tiseò, C.; Pistoia, F.; Sacco, S. Sustained response to onabotulinumtoxin A in patients with chronic migraine: Real-life data. J. Headache Pain 2020, 21, 40. [CrossRef]

70. Zidan, A.; Roe, C.; Burke, D.; Mejico, L. Onabotulinumtoxin A wear-off in chronic migraine, observational cohort study. J. Clin. Neurosci. 2019, 69, 237–240. [CrossRef]

71. Masters-Israilov, A.; Robbins, M.S. Onabotulinumtoxin A Wear-off Phenomenon in the Treatment of Chronic Migraine. Headache 2019, 59, 1753–1761. [CrossRef]

72. Quintas, S.; García-Azorín, D.; Heredia, P.; Talavera, B.; Gago-Veiga, A.B.; Guerrero, A.L. Wearing Off Response to Onabotulinumtoxin A in Chronic Migraine: Analysis in a Series of 193 Patients. Pain Med. 2019, 20, 1815–1821. [CrossRef] [PubMed]

73. Khan, F.A.; Mohammed, A.E.; Poongkunran, M.; Chimakurthy, A.; Pepper, M. Wearing Off Effect of OnabotulinumtoxinA Near the End of Treatment Cycle for Chronic Migraine: A 4-Year Clinical Experience. Headache 2020, 60, 430–440. [CrossRef] [PubMed]

74. Evidente, V.G.H.; Pappert, E.J. Botulinum toxin therapy for cervical dystonia: The science of dosing. Tremor Other Hyperkinet Mov (N. Y.) 2014, 4, 273. [CrossRef]

75. Ching, J.; Tinsley, A.; Rothrock, J. Prognosis Following Discontinuation of BotulinumA Therapy in “Super-responding” Chronic Migraine Patients. Headache 2019, 59, 1279–1285. [CrossRef] [PubMed]

76. Blumenfeld, A.M.; Silberstein, S.D.; Dodick, D.W.; Aurora, S.K.; Brin, M.F.; Binder, W.J. Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. Headache 2017, 57, 766–777. [CrossRef]

77. Bratbak, D.F.; Nordgård, S.; Stovner, L.J.; Linde, M.; Dodick, D.W.; Aschehoug, I.; Folvik, M.; Tronnvik, E. Pilot study of sphenopalatine injection of onabotulinumtoxinA for the treatment of intractable chronic migraine. Cephalalgia 2017, 37, 356–364. [CrossRef]

78. Kim, Y.G.; Bae, J.H.; Kim, H.; Wang, S.J.; Kim, S.T. A Proposal for Botulinum Toxin Type A Injection into the Temporal Region in Chronic Migraine Headache. Toxins 2020, 12, 214. [CrossRef] [PubMed]

79. Kara, M.; Gürçay, E.; Aydin, G.; Kaymak, B.; Sekizkardes, M.; Akinci, A.; Uludüz, D.; Özçakar, L. Botulinum toxin injections to cranial sutures for chronic migraine Rewinding the technique using ultrasound imaging. Toxicon 2019, 172, 19–22. [CrossRef]